Hyperuricemia and prognosis in chronic kidney disease

D.D. Ivanov, L.M. Savitska, Z.V. Babaenko

Abstract


The ratio of uricemia, magnesia, quality of life and functional reserve of the kidneys in CKD has not been completely determined yet. These rates were analysed in 145 patients, depending on the CKD 1–5 stages. The dynamics in hyperuricemia, magnesia, uricemia and BP was established to have an inverse correlation and form the quality of life in patients with CKD 5th stage. Conversely, uricemia positively correlates with blood pressure and functional renal reserve in CKD 1–3 stages. Patients with hyperuricemia and CKD 1–5 stages have a high quality of life and greater renal reserve than patients with normouricemia, but at the same time they have increased risk for developing cardiovascular and metabolic disorders. Further accumulation of data and their analysis are needed for practical recommendations, in particular the rational of the use of allopurinol, febuxostat, Мagnerot, depending on the degree of uricemia, magnesia, and CKD stage

Keywords


hyperuricemia and chronic kidney disease; gout and chronic kidney disease; quality of life in patients with chronic kidney disease; Magnerot; magnesemia in chronic kidney disease

References


Richette P, Doherty M, Pascual E, et al. EXTENDED REPORT 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016 July 25. doi: 10.1136/annrheumdis-2016-209707.

Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient preference and adherence. 2017 Apr;11:795-800. doi:10.2147/PPA.S97927.

Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Therapeutic AdvancesinMusculoskeletal Disease. 2016;8(4):145-59. doi: 10.1177/1759720X16646703.

Povoroznjuk VV, Dubeckaja GS. Hyperuricemia and gout: a modern view on the problem. Problems of osteology. 2012;15(3):19-25. (In Ukrainian).

Wang Y, et al. Association between dietary magnesium intake and hyperuricemia. PloSone. 2015;10(11):e0141079. doi: 10.1371/journal.pone.0141079.

Kravchun PG, Krapivko SA, Kravchun PP, Kadykova OI. Influence of magnesium orotate on lipid metabolism in patients with chronic heart failure with concomitant type 2 diabetes mellitus. International Journal of Endocrinology.2012;2(42):12-6. (In Russian).

Shen JI, Saxena AB, Vangala S, Dhaliwal SK, Winkelmayer WC. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study. BMC Nephrology. 2017 Jun 17;18(1):196.doi: 10.1186/s12882-017-0616-4.

Hozhenko AI, Kravchuk AV, Sirman VM, Nikitenko OP, Romaniv LV. Functional renal reserve: physiological value of renal reserve and substantiation of the method of its determination. Pochki. 2015;4(14):7-11. (In Ukrainian). doi: 10.22141/2307- 1257.0.4.14.2015.74890.

Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford, England). 2011;50(4):740-5. doi: 10.1093/rheumatology/keq346.

Ivanov DD, Ivanova MD. SP326 Febuxostat improves GFR and BP in non-diabetic adults with CKD 2-3: 4 years follow-up. Nephrology dialysis transplantation. 2015;30(3):486-7. doi: 10.1093/ndt/gfv191.46.

Savytska LM. The correlation between renal functional reserve and serum uric acid and quality of life in chronic kidney disease stage I–III. Pochki. 2017; 6(2):99-104. (In Ukrainian). doi: 10.22141/2307-1257.6.2.2017.102788.




DOI: https://doi.org/10.22141/2307-1257.6.3.2017.109031

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru